Saponins as vaccine adjuvants

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 13, Issue 1-2, 1996, Pages 1-55

  Kensil, Charlotte Read ^a  

^a Calypte Biomedical Corporation   (United States)

Author keywords

adjuvant; QS 21; Quil A; Quillaja saponaria; vaccine

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 5; KEYHOLE LIMPET HEMOCYANIN; MELANOMA VACCINE; MICROSPHERE; PHOSPHORYL LIPID A; QS 17; QS 18; QS 21; QS 7; QUIL A; SAPONIN DERIVATIVE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY AFFINITY; ANTIBODY RESPONSE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; DRUG MIXTURE; DRUG PURIFICATION; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOSTIMULATION; LIPID COMPOSITION; MELANOMA; NONHUMAN; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; SPECIES DIFFERENCE; T LYMPHOCYTE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGEN-ANTIBODY REACTIONS; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; FEASIBILITY STUDIES; IMMUNOGLOBULIN G; SAPONINS; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINES;

EID: 0029761791     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (178)

1. Birk, Y., Saponins, in Toxic Constituents in Plant Foodstuffs, Liener, I. E., Ed., Academic Press, New York, 169, 1969.
2. Pompei, R., Flore, O., Marccialis, M. A., Pani, A., and Loddo. B., Glycyrrhetinic acid inhibits virus growth and inactivates virus particles, Nature, 218, 689, 1979.
3. Ito, M., Nakashima, H., Baba, M., Pauwels, R., DeClercq, E., Shigeta, S., and Yamamoto, N., Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)], Antivir. Res., 7, 127, 1987.
4. Sidhu, G. S. and Oakenful, D. G., A mechanism for the hypocholesterolaemic activity of saponins, Br. J. Nutr., 55, 643, 1986.
5. Espinet, R. G, Nouveau vaccin antiaphteux a complexe glucoviral, Gac. Vet., 13, 268, 1951.
6. Vogel, F. R. and Powell, M. F., A compendium of vaccine adjuvants and excipients, in Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F. and Newman, M. J., Eds., Plenum Press, New York, 141, 1995.
7. Campbell, J. B. and Peerbaye, Y. A., Saponin, Res. Immunol., 143(5), 526, 1992.
8. Kensil, C. R., Newman, M. J., Coughlin, R. T., and Marciani, D. J., Novel adjuvants from Quillaja saponaria Molina, in AIDS Research Reviews, 3, Koff, W. C., Wong-Staal, F., and Kennedy, R. C., Eds., Marcel Dekker, Inc., New York, 379, 1993.
9. McClintock, E., Trees of Golden Gate Park: Three from South America, Pac. Hortic., 45, 18. 1984.
10. Dalsgaard, K., Thin-layer chromatographic fingerprinting of commercially available saponins, Dan. Tidsskr. Farm., 44, 327, 1970.
11. Bomford, R., Stapleton, M., Winsor, S., Beesley, J. E., Jessup, E. A., Price, K. R., and Fenwick, G. R., Adjuvanticity and ISCOM formation by structurally diverse saponins, Vaccine, 10(9), 572, 1992.
12. Edelman, R., An update on vaccine adjuvants in clinical trial, AIDS Res. Hum. Retroviruses, 8, 1409, 1992.
13. Kensil, C. R., Patel, U., Lennick, M., and Marciani, D., Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex, J. Immunol., 146, 431, 1991.
14. Strobbe, R., Charlier, G., van Aert, A., Debecq, J., and Leunen, J., Studies about the adjuvant activity of saponin fractions in foot and mouth disease vaccine: II. Irritation and adjuvant activity of saponin fractions obtained by chromatography on Sephadex G100, Arch. Exp. Vet. Med., 28, 385, 1974.
15. Dalsgaard, K., A study of the isolation and characterization of the saponin Quil A, Acta Vet. Scand. Suppl., 69, 1, 1978.
16. Dalsgaard, K. Saponin adjuvants. III. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in foot and mouth disease vaccines, Arch. Gesamte Virusforsch., 44, 243, 1974.
17. Kersten, G. F. A., Teerlink, T., Derks, H. J. G. M., Verkleij, A. J., Van Wezel, T. L., Crommelin, D. J. A., and Beuvery, E. C., Incorporation of the major outer membrane protein of Neisseria gonorrhoea in saponin-lipid complexes (ISCOMs): Chemical analysis, some structural features, and comparison of their immunogenicity with three other antigen delivery systems, Infect. Immun., 56(2), 432, 1988.
18. Higuchi, R., Tokimitsu, Y., and Komori, T., An acylated triterpenoid saponin from Quillaja saponaria, Phytochemistry, 27, 1165, 1988.
19. Kersten, G. F. A., Characterization of the immunological adjuvant Quil A, in Aspects of Iscoms: Analytical, Pharmaceutical, and Adjuvant Properties, Thesis, National Institute for Public Health and Environmental Protection, Bilthoven, the Netherlands, and The Department of Pharmaceutics, University of Utrecht, the Netherlands, 71, 1990.
20. Kensil, C. R., Wu, J.-Y., and Soltysik, S., Structural and immunological characterization of the vaccine adjuvant QS-21, in Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F. and Newman, M. J., Eds., Plenum Press, New York, 525, 1995.
21. Kensil, C. R., Soltysik, S., Patel, U., and Marciani, D. J., Structure/function relationship in adjuvants from Quillaja saponaria Molina, in Vaccines 92, Brown, F., Chanock, R. M., Ginsberg, H. S., and Lerner, R. A., Eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 35, 1992.
22. Cleland, J. L., Kensil, C. R., Lim, A., Jacobsen, N. E., Basa, L., Spellman, M., Wheeler, D. A., Wu, J.-Y., and Powell, M. F., The isomerization and formulation stability of the vaccine adjuvant QS-21, J. Pharm. Sci., 85, 22, 1996.
23. Morein, B., Sundquist, B., Höglond, S., Dalsgaard, K., and Osterhaus, A., ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses, Nature, 308, 457, 1984.
24. Özel, M., Höglund, S., Gelderbloom, H. R., and Morein, B., Quaternary structure of the immunostimulating complex (ISCOM), J. Ultrastruct. Mol. Struct. Res., 102, 240, 1989.
25. Merza, M. S., Linné, T., Höglund, S., Portetelle, D., Burny, A., and Morein, B., Bovine leukaemia virus ISCOMs: biochemical characterization, Vaccine, 7, 22, 1989.
26. Sundquist, B., Lövgren, K., Höglund, S., and Morein, B., Influenza virus ISCOMs: biochemical characterization, Vaccine, 6, 44, 1988.
27. Åkerblom, L., Strömstedt, K., Höglund, S., Osterhaus, A., and Morein, B., Formation and characterization of FeLV ISCOMs, Vaccine, 7, 142, 1989.
28. Trudel, M., Nadon, F., Séguin, C., Simard, C., and Lussier, G., Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory synctial virus, Vaccine, 7, 12, 1989.
29. Morein, B., The ISCOM antigen-presenting system, Nature, 271, 1988.
30. Pyle, S. W., Morein, B., Bess, J. W., Åkerblom, L, Nara, P. L., Nigida, S. M., Lerche, N. W., Robey, W. G, Fischinger, P. J., and Arthur, L. O., Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HTV-1) or the HIV-1 external envelope glycoprotein gp120, Vaccine, 7, 465, 1989.
31. Morein, B., Ekstrom, J., and Lövgren, K., Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into ISCOMs, J. Immunol. Methods, 128, 177, 1990.
32. Reid, G., Soluble proteins incorporate into ISCOMS after covalent attachment of fatty acid, Vaccine, 9, 597, 1992.
33. Rimmelzwaan, G. F., Siebelink, K. H. J., Huisman, R. C., Moss, B., Francis, M. J., and Osterhaus, A. D. M. E., Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes, J. Gen. Virol., 75, 2097, 1994.
34. Lövgren, K., Lindmark, J., Pipkorn, R., and Morein, B., Antigenic presentation of small molecules and peptides conjugated to a preformed ISCOM as carrier, J. Immunol. Methods, 98, 137, 1987.
35. Larsson, M., Lövgren, K., and Morein, B., Immunopotentiation of synthetic oligopeptides by chemical conjugation to ISCOMs, J. Immunol. Methods, 162, 257, 1993.
36. Sundquist, B., Dalsgaard, K., and Morein, B., Assay of detergents by rocket electrophoresis in agarose gels containing red blood cells: "Rocket hemolysis," Biochem. Biophys. Res. Commun., 114(2), 699, 1983.
37. Kersten, G. F. A., van de Put, A., Teerlink, T., Beuvery, E. C., and Crommelin, D. J. A., Immunogenicity of liposomes and ISCOMs containing the major outer membrane protein of Neisseria gonorrhoeae: Influence of protein content and liposomal bilayer composition, Infect. Immun., 56(6), 1661, 1988.
38. Eldridge, J. H, Staas, J. K., Meulbroek, J. A., McGhee, J. R., Tice, T. R., and Gilley, R. M., Biodegradable microspheres as a vaccine delivery system, Mol. Immunol., 28, 287, 1991.
39. Hanes, J., Chiba, M., and Langer, R., Polymer microspheres for vaccine delivery, in: Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F. and Newman, M. J., Eds., Plenum Press, New York, 1995, 389.
40. Allison, A. C., and Gregoriadis, G., Liposomes as immunological adjuvants, Nature, 252, 252, 1974.
41. Kramp, W. J., Six, H. R., and Kasel, J. A., Postimmunization clearance of liposome entrapped Adenovirus type 5 hexon, Proc. Soc. Exp. Biol. Med., 169, 135, 1982.
42. Alving, C. R., Liposomes as carriers for vaccines, in: Liposomes. From Biophysics to Therapeutics, Ostro, M. J., Ed., Marcel Dekker, Inc., New York, pp 195, 1987.
43. Cleland, J. L., Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems, in: Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F. and Newman, M. J., Eds., Plenum Press, New York, pp. 439, 1995.
44. Cleland, J. L., Powell, M. F., Lim, A., Barron, L., Berman, P. W., Eastman, D. J., Nunberg, J. H., Wrin, T., and Vennari, J. C., Development of a single-shot subunit vaccine for HIV-1, AIDS Res. Hum. Retroviruses, 10 (S2), S21, 1994.
45. + cytotoxic T cells, Vaccine, 12(1), 73, 1994.
46. Egerton, J. R., Laing, E. A., and Thorley, C. M. Effect of Quil A, a saponin derivative, on the response of sheep to alum precipitated Bacteroides nodosus vaccines, Vet. Sci. Commun., 2, 247, 1978.
47. López De Turiso, J. A., Cortés, E., Martínez, C., de Ybáñez, R. R., Simarro, I., Vela, C., and Casal, I., Recombinant vaccine for canine parvovirus in dogs, J. Virol., 66(5), 2748, 1992.
48. 3 and saponin is related to the immunogenicity of the antigen, Int. Arch. Allergy Appl. Immun., 75, 280, 1984.
49. Kensil, C. R., Newman, M. J., Coughlin, R. T., Soltysik, S., Bedore, D., Recchia, J., Wu, J.-Y., and Marciani, D. J. The use of Stimulon adjuvant to boost vaccine response, Vacc. Res., 2(4), 273, 1993.
50. Kirkley, J. E., Naylor, P. H., Marciani, D. J., Kensil, C. R., Newman, M., and Goldstein, A. L., QS-21 augments the antibody response to a synthetic peptide vaccine compared to alum, in Combination Therapies, Goldstein, A. L. and Garaci, E., Eds., Plenum Press, New York, 1992, 231.
51. Bomford, R., Stapleton, M., Winsor, S., McKnight, A., and Andronova, T. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants, AIDS Res. Hum. Retroviruses, 8, 1765, 1992.
52. Brett, S. J., Dunlop, L., Liew, F. Y., and Tite, J. P., Influence of the antigen delivery system on immunoglobulin isotype selection and cytokine production in response to influenza A nucleoprotein, Immunology, 80, 306, 1993.
53. Allison, A. C., and Byars, N. E., An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity, J. Immunol. Methods, 95, 157, 1986.
54. Klaus, G. G. B., Pepys, M. B., Kitajima, K., and Askonas, B. A., Activation of mouse complement by different classes of mouse antibody, Immunology, 38, 687, 1979.
55. Coutelier, J.-P., Van Der Logt, J. T. M., Heessen, F. W. A., Warnier, G., and Van Snick, J., IgG2a restriction of murine antibodies elicited by viral infections, J. Exp. Med., 165, 64, 1987.
56. Karagouni, E. E., and Hadjipetrou-Kourounakis, L., Regulation of isotype immunoglobulin production by adjuvants in vivo, Scand. J. Immunol., 31, 745, 1990.
57. Tiong, G. K. L., Harsharnjit, S. G., Lofthouse, S., and Puri, N. K., Comparison of conventional adjuvants and "adjuvant-free" monoclonal antibody targeting for stimulating antibody responses against a conjugate of luteinizing hormone releasing hormone and avidin, Vaccine, 11, 425, 1993.
58. Kenney, J. S., Hughes, B. W., Masada, M. P., and Allison, A. C., Influence of adjuvants on the quantity, affinity, isotype, and epitope specificity of murine antibodies, J. Immunol. Methods, 121, 157, 1989.
59. Ma, J., Bulger, P. A., van Riet Davis, D., Perilli-Palmer, B., Bedore, D. A., Kensil, C. R., Young, E. M., Hung, C.-H., Seals, J. R., Pavia, C. S., and Coughlin, R. T., Impact of the saponin adjuvant QS-21 and aluminum hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi, Vaccine, 12(10), 925, 1994.
60. Kensil, C. R., Barrett, C., Kushner, N., Beltz, G., Storey, J., Patel, U., Recchia, J., Aubert, A., and Marciani, D., Development of a genetically engineered vaccine against feline leukemia virus infection, J. Am. Vet. Med. Assoc., 10, 1423, 1991.
61. Britt, W., Fay, J., Seals, J., and Kensil, C., Formulation of an immunogenic human cytomegalovirus vaccine: Responses in mice. J. Infect Dis., 171, 18, 1995.
62. Hancock, G. E., Speelman, D. J., Frenchick, P. J., Mineo-Kuhn, M. M., Baggs, R. B., and Hahn, D. J., Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection, Vaccine, 13 (4), 391, 1995.
63. Coughlin, R. T., Fattom, A., Chu, C., White, A. C., and Winston, S., Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines, Vaccine, 13 (1), 17, 1995.
64. Newman, M. J., Wu, J.-Y., Coughlin, R. T., Murphy, C. I., Seals, J. R., Wyand, M. S., and Kensil, C. R., Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in non-human primates, AIDS Res. Hum. Retroviruses, 8, 1413, 1992.
65. Mond, J. J., Lees, A., and Snapper, C. M., T cell-independent antigens Type 2, Annu. Rev. Immunol., 13, 655, 1995.
66. Golding, B., Cytokine regulation on humoral immune responses, in Topics in Vaccine Adjuvant Research, D. R. Spriggs, W. C. Koff, Eds., CRC Press. Boca Raton, 25, 1991.
67. Flebbe, L. M. and Braley-Mullen, H. Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens, Cell. Immunol., 99, 119, 1986.
68. Flebbe, L. M. and Braley-Mullen, H. Immunopotentiation by SGP and Quil A. II. Identification of responding cell populations, Cell. Immunol., 99, 128, 1986.
69. Van Nest, G. A., Steimer, K. S., Haigwood, N. L., Burke, R. L., and Ott, G., Advanced adjuvant formulations for use with recombinant subunit vaccines, in: Vaccines 92: Modern Approaches to New Vaccines, Chanock R. M., Lerner R. A., Brown F., and Ginsburg H., Eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 57, 1992.
70. Flynn, J. N., Cannon, C. A., Beatty, J. A., Mackett, M., Rigby, M. A., Neil, J. C., and Jarrett, O., Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide. J. Virol., 68(9), 5835, 1994.
71. Langeveld, J. P. M., Casal, J. I., Cortés, E., van de Wetering, G., Boshuizen, R. S., Schaaper, W. M. M., Dalsgaard, K., and Meloen, R. H., Effective induction of neutralizing antibodies with the amino terminus of VP2 of canine parvovirus as a synthetic peptide, Vaccine, 12(15), 1473, 1994.
72. Emery, D. L., Rothel, J. S., and Wood, P. R., Influence of antigens and adjuvants on the production of gamma-interferon and antibody by ovine lymphocytes, Immunol. Cell. Biol., 68, 127, 1990.
73. Houdayer, M., Rouze, P., Dalsgaard, K., and Metzger, J. J., Adjuvant effect of Quil-A on the porcine humoral immune response, Ann. Immunol. (Inst. Pasteur), 129C, 107, 1978.
74. Ma, J., Bulger, P. A., Dante, S., van Riet Davis, D., Perilli-Palmer, B., and Coughlin, R. T, Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes, J. Infect. Dis., 171, 909, 1995.
75. Smith, R. D., James, M. A., Ristic, M, Aikawa, M., and Vega y Murguia, C. A., Bovine babesiosis: Protection of cattle with culture-derived soluble Babesia bovis antigen, Science, 212, 335, 1981.
76. Stott, E. J., Chan, W. L., Mills, K. H. G., Page, M., Taffs, F., Cranage, M., Greenaway, P., and Kitchin, P., Preliminary report: Protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine, Lancer, 336, 1538, 1990.
77. Marciani, D. J., Kensil, C. R., Beltz, G. A., Hung, C. H., Cronier, J., and Aubert, A., Genetically-engineered subunit vaccine against feline leukaemia virus: Protective immune response in cats, Vaccine, 9, 89, 1991.
78. Clark, N., Kushner, N. N., Barrett, C. B., Kensil, C. R., Salsbury, D., and Cotter, S., Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection, J. Am. Vet. Med. Assoc., 199(10), 1433, 1991.
79. Powell, M. F., Eastman, D. J., Lim, A., Lucas, C., Peterson, M., Vennari, J., Weissburg, R. P., Wrin, T., Kensil, C. R., Newman, M. J., Nunberg, J., Cleland, J. L., Gregory, T. J., and Berman, P. W., Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs, AIDS Res. Hum. Retroviruses, 11, 203, 1995.
80. Powell, M. E., Cleland, J. L., Eastman, D. J., Lim, A., Newman, M. J., Nunberg, J. H., Weissburg, R. P., Vennari, J. C., Wrin, T., and Berman, P. W., Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HTV-1 QS21 vaccine in baboons, AIDS Res. Hum. Retroviruses, 10(S2), S105, 1994.
81. Coughlin, R. T., Fish, D., Mather, T. N., Ma, J., Pavia, C., and Bulger, P., Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp)A, OspB, and the saponin adjuvant QS-21, J. Infect. Dis., 171(4), 1049, 1995.
82. Townsend, A. and Bodmer, H., Antigen recognition by class I-restricted T lymphocytes, Annu. Rev. Immunol., 7, 601, 1989.
83. Yewdell, J. W. and Bennink, J. R., The binary logic of antigen processing and presentation to T cells, Cell, 62, 203, 1990.
84. Pfeifer, J. D., Wick, M. J., Roberts, R. L., Findlay, K., Normark, S. J. and Handing, C. V., Phagocytic processing of bacterial antigen for class IMHC presentation to T cells. Nature, 361, 359, 1993.
85. Kovacsovics-Bankowski, M. and Rock, K. L., A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules, Science, 267, 243, 1995.
86. + cytotoxic T lymphocytes, J. Exp. Med., 176, 1739, 1992.
87. Deres, K., Schild, H., Weismuller, K., Jung, G., and Rammensee, H., In vivo priming of cytotoxic T lymphocytes with synthetic lipopeptide vaccine, Nature, 342, 561, 1989.
88. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMS, Nature, 344, 873, 1990.
89. + cytotoxic T lymphocytes towards soluble antigens: Immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide, Eur. J. Immunol., 21, 1523, 1991.
90. + CTL in vivo with peptide vaccine constructs, J. Immunol., 152, 549, 1994.
91. Wu, J.-Y., Gardner, B. H., Murphy, C. I., Seals, J. R., Kensil, C. R., Recchia, J., Beltz, G. A., Newman, G. W., and Newman, M. J., Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine, J. Immunol., 148, 1519, 1992.
92. + cytotoxic T lymphocyte responses, J. Immunol., 148, 2357, 1992.
93. mac251 gag and env vaccines containing QS-21 saponin adjuvant, AIDS Res. Hum. Retroviruses, 10(7), 853, 1994.
94. Munroe, K. J., Anderson, C. A., Wu, J.-Y., Wyand, M. S., Newman, G. W., and Newman, M. J., Use of fixed autologous stimulator cells to correctly present human immunodeficiency virus type 1 viral peptides to nonhuman primate lymphocytes in proliferation and cytotoxic T-lymphocyte assays, Clin. Diagn. Lab. Immunol., 1(3), 283, 1994.
95. Campbell, J. B., Maharaj, I., and Roith, J., Vaccine formulations for oral immunization of laboratory animals and wildlife against rabies, in Rabies in the Tropics, Kwert, E., Merieux, C., Koprowski, H., and Bögel, K., Eds., Springer Verlag, 1985, 285.
96. Chavali, S. R. and Campbell, J. B., Adjuvant effects of orally administered saponins on humoral and cellular immune responses in mice, Immunobiology, 174, 347, 1987.
97. Maharaj, I., Froh, K. J., and Campbell, J. B., Immune responses of mice to inactivated rabies vaccine administered orally: Potentiation by Quillaja saponin, Can. J. Microbiol., 32, 414, 1986.
98. Chavali, S. R., Barton, L. D., and Campbell, J. B., Immunopotentiation by orally administered Quillaja saponins: Effects in mice vaccinated intraperitoneally against rabies, Clin. Exp. Immunol., 74, 339, 1988.
99. Chavali, S. R. and Campbell, J. B., Immunomodulatory effects of orally administered saponins and nonspecific resistance against Rabies infection, Int. Arch. Allergy Appl. Immun., 84, 129, 1987.
100. Mowat, A. McI., Maloy, K. J., and Donachie, A. M., Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens, Immunology, 80, 527, 1993.
101. Lövgren, K., Kåberg, H., and Morein, B., An experimental influenza subunit vaccine (ISCOM): Induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration, Clin. Exp. Immunol., 82, 435, 1990.
102. Ben Ahmeida, E. T. S., Gregoriadis, G., Potter, C. W., and Jennings, R., Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes, and FCA: Role in protection against influenza A in mice, Vaccine, 11(13), 1302, 1993.
103. Loftager, M. K., Eriksen, L, Aasted, B., and Nielsen, R., Protective immunity following immunisation of pigs with aerosol of Actinobacillus pleuropneumoniae serotype 2, Res. Vet. Sci., 55, 281, 1993.
104. Thapar, M. A., Parr, E. L., Bozzola, J. J., and Parr, M. B., Secretory immune responses in mouse vagina after parenteral or intravaginal administration with an immunostimulating complex (ISCOM), Vaccine, 9, 129, 1991.
105. Osterhaus, A., Weijer, K., UytdeHaag, F., Knell, P., Jarrett, O., Åkerblom, L., and Morein, B., Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine, Vaccine, 7, 137, 1989.
106. Sundquist, B., Lövgren, K., and Morein, B., Influenza virus ISCOMs: Antibody response in animals, Vaccine, 6, 49, 1988.
107. Jones, P. D., Tha Hla, R., Morein, B., Lövgren, K., and Ada, G. L., Cellular immune response in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (ISCOMs), Scand. J., Immunol., 27, 645, 1988.
108. Ertürk, M., Jennings, R., Hockley, D., and Potter, C. W., Antibody responses and protection in mice immunized with Herpes simplex type 1 antigen immune-stimulating complex preparations, J. Gen. Virol., 70, 2149, 1989.
109. Mougin, B., Bakouche, O., and Gerlier, D., Humoral immune response elicited in rats by measles viral membrane antigens presented in liposomes and ISCOMs, Vaccine, 6, 445, 1988.
110. Putonken, P., Björling, E., Åkerblom, L., Thorstensson, R., Lövgren, K., Benthin, L., Chiodi, F., Morein, B., Biberfeld, G., Norrby, E., and Wigzell, H., Long-standing protection of macaques against cell-free HIV-2 with an HIV-2ISCOM vaccine, J. Acq. Immun. Def. Syndr., 7, 551, 1994.
111. Verheul, A. F. M., Versteeg, A. A., De Reuver, M. J., Jansze, M., and Snippe, H., Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates, Infect. Immun., 57(4), 1078, 1989.
112. White, A. C., Cloutier, P., and Coughlin, R. T., A purified saponin acts as an adjuvant for a T-independent antigen, in Immunobiology of Proteins and Peptides VI, Atassi, M. Z., Ed., Plenum Press, New York, 1991.
113. Verheul, A. F. M., Versteeg, A. A., Westerdaal, N. A. C., Van Dam, G. J, Jansze, M., and Snippe, H., Measurement of the humoral immune response against Streptococcus pneumoniae type 14-derived antigens by an ELISA and ELISPOT assay based on biotin-avidin technology, J. Immunol. Methods, 126, 79, 1990.
114. van de Wijgert, J. H. H. M., Verheul, A. F. M., Snippe, H., Check, I. J., and Hunter, R. L., Immunogenicity of Streptococcus pneumoniae Type 14 capsular polysaccharide: Influence of carriers and adjuvants on isotype distribution, Infect. Immun., 59(8), 2750, 1991.
115. AlonsoDeVelasco, E., Dekker, H. A. Th., Antal, P., Jalink, K. P., van Strijp, J. A. G., Verheul, A. F. M., Verhoef, J., and Snippe, H., Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines, Vaccine, 12, 1419, 1994.
116. Verheul, A. F. M., Poolman, J. T., Snippe, H., and Verhoef, J., The influence of the adjuvant Quil A on the epitope specificity of meningococcal lipopolysaccharide anti-carbohydrate antibodies, Mol. Immun., 28 (11), 1193, 1991.
117. Verheul, A. F. M., Braat, A. K., Leenhouts, J. M., Hoogerhout, P., Poolman, J. T., Snippe, H., and Verhoef, J., Preparation, characterization, and immunogenicity of Meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates, Infect. Immun., 59(3), 843, 1991.
118. Verheul, A. F. M., Van Gaans, J. A. M., Wiertz, E. J. H., Snippe, H., Verhoef, J., and Poolman, J. T., Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: Influence of adjuvants, Infect. Immun., 61(1), 187, 1993.
119. Golovliov, I., Ericsson, M., Åkerblom, L., Sandström, G., Tärnvik, A., and Sjostedt, A., Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis, Vaccine, 13(3), 261, 1995.
120. + cytolytic T cells and confers protection to infection, Immunol. Lett., 40, 101, 1994.
121. Sher, A. and Coffman, R. L., Regulation of immunity to parasites by T cells and T cell-derived cytokines, Annu. Rev. Immunol., 10, 385, 1995.
122. McColm, A. A., Bomford, R., and Dalton, L., A comparison of saponin with other adjuvants for the potentiation of protective immunity by a killed Plasmodium yoelii vaccine in the mouse, Parasite Immunol., 4, 337, 1982.
123. White, W. I., Evans, C. B., and Taylor, D. W., Antimalarial antibodies of the immunoglobulin G2a isotype modulate parasitemias in mice infected with Plasmodium yoelii, Infect. Immun., 59, 3547, 1991.
124. Ten Hagen, T. L. M., Sulzer, A. J., Kidd, M. R., Lal, A. A., and Hunter, R. L., Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines, J. Immunol., 151, 7077, 1993.
125. Heath, A. W., Devey, M. E., Brown, I. N., Richards, C. E., and Playfair, J. H. L., Interferon-gamma as an adjuvant in immunocompromised mice, Immunology, 67, 520, 1989.
126. + T-cell immunity against fatal Toxoplasma gondii infection in mice, J. Immunol., 147, 3501, 1991.
127. Araujo, F. G. and Morein, B., Immunization with Trypanosoma cruzi epimastigote antigens incorporated into Iscoms protects against lethal challenge in mice, Infect. Immun., 59(9), 2909, 1991.
128. Lundén, A., Lövgren, K., Uggla, A., and Araujo, F. G., Immune responses and resistance to Toxoplasma gondii in mice immunized with antigens of the parasite incorporated into immunostimulating complexes, Infect. Immun., 61(6), 2639, 1993.
129. Sjolander, A., Lövgren, K., Stahl, S., Aslund, L., Hansson, M., Nygren, P.-A., Larsson, M., Hagstedt, M., Wahlin, B., Berzins, K., Uhlen, M., Morein, B., and Perlmann, P., High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA, Vaccine, 9, 443, 1991.
130. James, S. L. and Pearce, E. J., The influence of adjuvant on induction of protective immunity by a non-living vaccine against schistosomiasis, J. Immunol., 140, 2753, 1988.
131. Livingston, P. O., Koganty, R., Longenecker, B. M., Lloyd, K. O., and Calves, M., Studies on the immunogenicity of synthetic and natural Thomsen-Friedenreich (TF) antigens in mice: Augmentation of the response by Quil A and SAF-m adjuvants and analysis of the specificity of the responses, Vacc. Res., 1(2), 99, 1992.
132. D3 vaccines for melanoma: Superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines, Cancer Res., 54, 197, 1994.
133. Petermann, H. G., Soulebot, J. P., Lang, R., and Branche, R., Saponin, an immune adjuvant for vaccinating cattle against rabies, C. R. Acad. Sci, Ser. D, 270, 234, 1970.
134. Frenkel, S., Barendregt, L. G., Kloosterman, E. G., and Talmon, F. P., Serological response of calves to aluminium hydroxide gel FMD vaccine with or without saponin. Influence of genetic differences on this response, XVI Conf. Ft Mouth Dis. Comm., 171, 1982.
135. George, A. J., Legal status and toxicity of saponins, Fd. Cosmet. Toxicol., 3, 85, 1965.
136. Phillips, J. C., Butterworth, K. R., Gaunt, I. F., Evans, J. G., and Grasso, P., Long-term toxicity study of Quillaia extract in mice, Fd. Cosmet. Toxicol., 17, 23, 1979.
137. Drake, J. J.-P., Butterworth, K. R., Gaunt, I. F., Hooson, J., Evans, J. G., and Gangolli, S. D., Long-term toxicity study of Quillaia extract in rats, Fd. Chem. Toxicol., 20, 15, 1982.
138. Vanselow, B. A., Abetz, I., and Trenfield, K., A bovine ephemeral fever vaccine incorporating adjuvant Quil A: A comparative study using adjuvants Quil A, aluminum hydroxide gel and dextran sulfate, Vet. Rec., 117, 37, 1985.
139. Speijers, G. J. A., Danse, L. H. J. C., Beuvery, E. C., Strik, J. J. T. W. A., and Vos, J. G., Local reactions of the saponin Quil A and a Quil A containing ISCOM measles vaccine after intramuscular injection of rats: A comparison with the effect of DPT-Polio Vaccine, Fundam. Appl. Toxicol., 10, 425, 1988.
140. Stieneker, F., Kersten, G., van Bloois, L., Crommelin, D. J. A., Hem, S. L., Lower, J., and Kreuter, J., Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations, Vaccine, 13(1), 45, 1995.
141. Warren, H. S. and Chedid, L. A., Future prospects for vaccine adjuvants, Crit. Rev. Immunol., 8(2), 83, 1988.
142. Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., Ben-Efraim, S., and Gupta, C. K., Adjuvants - a balance between toxicity and adjuvanticity, Vaccine, 11(3), 293, 1993.
143. M2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma, Vaccine, 12, 1275, 1994.
144. Livingston, P. O., Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines, Ann. NY Acad. Sci., 690, 204, 1993.
145. Livingston, P. O., Adluri, S., Zhang, S., Chapman, P., Raychaudhuri, S., and Merritt, J. A., Impact of immunological adjuvants and administration route on HAMA response after immunization with murine monoclonal antibody MELIMMUNE-1 in melanoma patients, Vacc. Res., 4(2), 87, 1995.
146. M2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21, Cancer Res., 55, 2783, 1995.
147. Chedid, L., Adjuvants of immunity. Ann. Immunol. (Inst. Pasteur), 136D, 283, 1985.
148. Scott, M. T., Goss-Sampson, M., and Bomford, R., Adjuvant activity of saponin: Antigen localization studies, Int. Arch. Allergy Appl. Immun., 77, 409, 1985.
149. Watson, D. L., Lövgren, K., Watson, N. A., Fossum, C., Morein, B., and Höglund, S., Inflammatory response and antigen localization following immunization with influenza virus ISCOMs, Inflammation, 13(6), 641, 1989.
150. Bomford, R., Studies on the cellular site of action of the adjuvant activity of saponin for sheep erythrocytes, Int. Arch. Allergy Appl. Immun., 67, 127, 1982.
151. Wu, J.-Y., Gardner, B. H., Kushner, N. N., Pozzi, L. M., Kensil, C. R., Cloutier, P. A., Coughlin, R. T., and Newman, M. J., Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes, Cell. Immunol., 154, 393, 1994.
152. Allison, A. C., Harington, J. S., and Birbeck, M., An examination of the cytotoxic effects of silica on macrophages, J. Exp. Med., 124, 141, 1966.
153. Morein, B., Villacrés-Eriksson, M., Åkerblom, L, Rönnberg, B., Lövgren, K., and Sjölander, A., Mechanisms behind the immune stimulating response induced by immunostimulating complexes, AIDS Res. Hum. Retroviruses, 10(S2), S109, 1994.
154. Fossum, C., Bergström, M., Lövgren, K., Watson, D. L., and Morein, B., Effect of ISCOMs and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: Comparison of spleen cells from mice inoculated with ISCOMs and/or matrix, Cell. Immunol., 129, 414, 1990.
155. Wu, J.-Y., Munroe, K. J., Gardner, B. H., Wyand, M. S., and Newman, M. J., Use of particulate forms of protein antigens to increase the sensitivity of antigen-specific proliferation assays, J. Immunol. Methods, 159, 39, 1993.
156. Chaviali, S. R., Francis, T., and Campbell, J. B., An in vitro study of immunomodulatory effects of some saponins, Int. J. Immunopharmac., 9, 675, 1987.
157. Snapper, C. M., and Paul, W. E., Interferon-γ and B-cell stimulatory factor-1 reciprocally regulate Ig isotype production, Science, 236, 944, 1987.
158. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., and Coffman, R. L., Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins, J. Immunol., 136(7), 2348, 1986.
159. Stevens, T. L., Bossie, A., Sanders, V. M., Fernandez-Botran, R., Coffman, R. L., Mosmann, T. R., and Vitetta, E. S., Regulation of antibody isotype secretion by subsets of antigen-specific helper T-cells, Nature, 334, 255, 1988.
160. Heath, A. W., Nyan, O., Richards, C. E., and Playfair, J. H. L., Effects of interferon gamma and saponin on lymphocyte traffic are inversely related to adjuvanticity and enhancement of MHC Class II expression, Int. Immunol. 3(3), 285, 1991.
161. Watson, D. L., Watson, N. A., Fossum, C., Lövgren, K., and Morein, B., Interactions between immune-stimulating complexes (ISCOMs) and peritoneal mononuclear leukocytes, Microbiol. Immunol., 36(2), 199, 1992.
162. Bergström-Mollaoglu, M., Lövgren, K., Åkerblom, L., Fossum, C., and Morein, B., Antigen-specific increases in the number of splenocytes expressing MHC Class II molecules following restimulation with antigen in various physical forms, Scand. J. Immunol., 36, 565, 1992.
163. Maraskovsky, E., Chen, W.-F., and Shortman, K., IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T cells, J. Immunol., 143, 1210, 1989.
164. Villacres-Eriksson, M., Bergström-Mollaoglu, M., Kåberg, H., and Morein, B., Involvement of interleukin-2 and interferon-gamma in the immune response induced by influenza virus ISCOMs, Scand. J. Immunol., 36, 421, 1992.
165. Valensi, J.-P. M., Carlson, J. R., and Van Nest, G. A., Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants, J. Immunol., 153, 4029, 1994.
166. Villacres-Eriksson, M., Bergström-Mollaoglu, M., Kåberg, H., Lövgren, K., and Morein, B., The induction of cell-associated and secreted IL-1 by ISCOMs, matrix, or micelles in murine splenic cells, Clin. Exp. Immunol., 93, 120, 1993.
167. Labriola, R. A. and Deulofeu, V., The structure of prosapogenin from Quillaja saponaria, Experentia, 25, 124 1968.
168. Higuchi, R., Tokimitsu, Y., Fujioka, T., Komori, T., Kawasaki, T., and Oakenful, D. G., Structure of desacylsaponins obtained from the bark of Quillaja saponaria, Photochemistry, 26, 229, 1987.
169. Higuchi, R., and Komori, T., Structures of compounds derived from the acyl moieties of quillajasaponin, Phytochemistry, 26, 2357, 1987.
170. 13C-NMR spectroscopy, Carbohydr. Res., 280, 1, 1996.
171. Soltysik, S., Bedore, D. A., and Kensil, C. R., Adjuvant activity of QS-21 isomers, Ann, NY Acad. Sci., 690, 392, 1993.
172. Soltysik, S., Wu, J.-Y., Recchia, J., Wheeler, D. A., Newman, M. J., Coughlin, R. T., and Kensil, C. R., Structure/function studies of QS-21 adjuvant: Assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function, Vaccine, 13, 1403, 1995.
173. Rhodes, J., Evidence for an intercellular covalent reaction essential in antigen-specific T cell activation, J. Immunol., 143, 1482, 1989.
174. Kersten, G. F. A., Spiekstra, A., Beuvery, E. C., and Crommelin, D. J. A., On the structure of immune-stimulating saponin-lipid complexes (ISCOMs), Biochem. Biophys. Acta, 1062, 165, 1991.
175. Kensil, C. R. and Marciani, D. J., Saponin adjuvant, U.S. Patent # 5,057,540, 1991.
176. Bomford, R., Saponin and other haemolysins (vitamin A, aliphatic amines, polyene antibiotics) as adjuvants for SRBC in the mouse, Int. Arch. Allergy Appl. Immun., 63, 170, 1980.
177. Glauert, A. M., Dingle, J. T., and Lucy, J. A., Action of saponins on biological membranes, Nature, 196, 953, 1962.
178. Bangham, A. D. and Horne, R. W., Action of saponins on biological membranes, Nature, 196, 952, 1962.